OOIR: Observatory of International Research

Papers

(The H4-Index of npj Vaccines is 43. The table below lists those papers that are above that threshold based on CrossRef citation counts [max. 250 papers]. The publications cover those that have been published in the past four years, i.e., from 2022-08-01 to 2026-08-01.)

Article	Citations
Immunogenicity phase II study evaluating booster capacity of nonadjuvanted AKS-452 SARS-Cov-2 RBD Fc vaccine	225
Analyzing atomic force microscopy images of virus-like particles by expectation-maximization	166
Vaccination against Onchocerca volvulus induces IgG-mediated protective immunity dependent on neutrophils and complement	141
Tetravalent microprojection-based dengue chimeric virus vaccine raises potent neutralising antibodies in mice	131
The dengue-specific immune response and antibody identification with machine learning	120
A potent and durable malaria transmission-blocking vaccine designed from a single-component 60-copy Pfs230D1 nanoparticle	118
Immunogenic arenavirus vector SIV vaccine reduces setpoint viral load in SIV-challenged rhesus monkeys	111
Immunogenicity and safety of a rabies-based highly pathogenic influenza A virus H5 vaccine in cattle	110
Effective vaccination strategy using SARS-CoV-2 spike cocktail against Omicron and other variants of concern	99
Immunogenicity of PCV13 during Hospitalization soon after infection resolution: Vaccis study	89
Risk assessment of retinal vascular occlusion after COVID-19 vaccination	89
A viral codon usage strategy enhances antigen production and protection in SFTSV mRNA vaccination	86
Intranasal vaccine for Lyme disease provides protection against tick transmitted Borrelia burgdorferi beyond one year	85
Assessing immunogenicity barriers of the HIV-1 envelope trimer	81
Functionality and translation fidelity characterization of mRNA vaccines using platform based mass spectrometry detection	78
Impact of genotypic variability of measles virus T-cell epitopes on vaccine-induced T-cell immunity	75
Influenza A virus in dairy cattle: infection biology and potential mammary gland-targeted vaccines	75
Safety and immunogenicity of the Sm-p80 GLA-SE schistosomiasis vaccine	75
Intranasal and intramuscular H5-Matrix-M nanoparticle vaccines protects against highly pathogenic H5N1 influenza virus in mice	71
Mapping global public perspectives on mRNA vaccines and therapeutics	71
Zika purified inactivated virus (ZPIV) vaccine reduced vertical transmission in pregnant immunocompetent mice	70
Reverse development of vaccines against antimicrobial-resistant pathogens	68
Use of equine H3N8 hemagglutinin as a broadly protective influenza vaccine immunogen	66
Single-dose intranasal adenovirus-based RSV vaccines targeting G and M2	64
Immunogenicity of one and two doses of Gardasil®9 in Tanzanian girls in the DoRIS Trial	63

Tick-borne encephalitis vaccine breakthrough infections induce aberrant T cell and antibody responses to non-structural proteins	62
Next-gen novel nanocage-based multivalent vaccine candidate to tackle the rising menace of Mpox	58
mRNA-LNP vaccine encoding CDV hemagglutinin confers effective protection in raccoon dogs	57
Immunogenicity and protective efficacy of a rhesus adenoviral vaccine targeting conserved COVID-19 replication transcription complex	56
Vaccination with Mincle agonist UM-1098 and mycobacterial antigens induces protective Th1 and Th17 responses	52
PfRH5 vaccine; from the bench to the vial	52
SARS-CoV-2 vaccination may mitigate dysregulation of IL-1/IL-18 and gastrointestinal symptoms of the post-COVID-19 condition	52
Immunogenicity and efficacy of homologous and heterologous NDV and MVA SARS-CoV-2 vaccines in mice and hamsters	52
A rationally designed antigen elicits protective antibodies against multiple nosocomial Gram-positive pathogens	51
Titers of antibodies against ancestral SARS-CoV-2 correlate with levels of neutralizing antibodies to multiple variants	50
Novel enzymatic DNA produced from a text file achieves comparable immune responses as plasmid vaccine	49
Author Correction: A Pvs25 mRNA vaccine induces complete and durable transmission-blocking immunity to Plasmodium vivax	48
Multi-antigen DNA vaccine targeting non-structural proteins confers robust T Cell-mediated protection against Zika virus	47
Human in vitro modeling of adjuvant formulations demonstrates enhancement of immune responses to SARS-CoV-2 antigen	47
Diversity of immunization strongly impacts SARS-CoV-2 antibody function surrogates	46
A field test of empathetic refutational and motivational interviewing to address vaccine hesitancy among patients	45
Development of a multi-epitope mRNA vaccine targeting tumor-associated antigens for esophageal squamous cell carcinoma	44
Optimization of heroin conjugate vaccine performance in rodent models	43